This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Friends Research Institute, Inc.
ClinicalTrials.gov Identifier:
NCT01131520
First received: May 21, 2010
Last updated: July 19, 2017
Last verified: July 2017
  Purpose
The purpose of this study is to compare the effectiveness in reducing drug use and its associated problems of a brief intervention for drug use delivered by a behavioral health counselor as compared to a brief intervention delivered by a computerized intervention.

Condition Intervention
Drug Abuse HIV Risk Behavior Behavioral: Computerized brief intervention Behavioral: Counselor delivered brief intervention

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SBIRT in New Mexico

Further study details as provided by Friends Research Institute, Inc.:

Primary Outcome Measures:
  • Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score [ Time Frame: 3 months post-baseline ]
    The ASSIST's Global Continuum of Illicit Drug Risk was used. A higher score is considered more severe risk. The scores range from 0 to 308.

  • Hair Testing [ Time Frame: 3 month post-baseline ]
    The number of participants testing positive on Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and tetrahydrocannabinol (THC)


Secondary Outcome Measures:
  • Human Immunodeficiency Virus (HIV) Drug Use Risk Assessment Battery Subscale [ Time Frame: 3 months post-baseline ]
    HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.

  • Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score [ Time Frame: 6 month post-baseline ]
    ASSIST's Global Continuum of Illicit Drug Risk Score which ranges from 0 to 308. A higher score is associated with higher risk.

  • Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score [ Time Frame: 12 months post-baseline ]
    ASSIST's Global Continuum of Illicit Drug Risk Score which ranges from 0 to 308. A higher score is associated with higher risk.

  • Hair Testing [ Time Frame: 6 month post-baseline ]
    The predicted probabilities for testing positive on Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and tetrahydrocannabinol (THC), calculated from generalized estimating equations.

  • Hair Testing [ Time Frame: 12 month post-baseline ]
    Predicted Probabilities for testing positive on the Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and THC, calculated from generalized estimating equations.

  • Human Immunodeficiency Virus (HIV) Risk Assessment Battery Subscale [ Time Frame: 6 month post-baseline ]
    HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.

  • Human Immunodeficiency Virus (HIV) Risk Assessment Battery Subscale Score [ Time Frame: 12 month post-baseline ]
    HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.


Enrollment: 360
Study Start Date: June 2010
Study Completion Date: July 2015
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Computerized Brief Intervention
Computerized one-session brief intervention for drug use
Behavioral: Computerized brief intervention
This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
Active Comparator: Counselor delivered brief intervention
This is a brief intervention focused on drug use delivered by a behavioral health counselor and based on motivational interviewing
Behavioral: Counselor delivered brief intervention
This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.

Detailed Description:
Drug use is a significant cause of morbidity and mortality in the United States. Efforts to develop and rigorously evaluate methods to provide Screening, Brief Intervention and Referral to Treatment (SBIRT) for drug users are needed. Computerized screening and brief interventions in particular have the potential to circumvent some of the potential problems of integrating SBIRT delivered by a counselor into busy primary care settings. These interventions may reduce drug use among individuals who are using drugs but are not yet drug dependent.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years or older
  • Moderate risk category on the ASSIST scores

Exclusion Criteria:

  • planning to move out of New Mexico in the next year
  • receipt of formal drug abuse treatment or a brief intervention for drug use in the past month.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01131520

Locations
United States, Maryland
Friends Research Institute
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Robert P Schwartz, M.D. Friends Research Institute, Inc.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Friends Research Institute, Inc.
ClinicalTrials.gov Identifier: NCT01131520     History of Changes
Other Study ID Numbers: 08-08-173
R01DA026003 ( U.S. NIH Grant/Contract )
Study First Received: May 21, 2010
Results First Received: December 20, 2016
Last Updated: July 19, 2017

Keywords provided by Friends Research Institute, Inc.:
SBIRT
Drug abuse

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 25, 2017